Object. The appropriate dose during stereotactic radiosurgery (SRS) of cerebral arteriovenous malformations (AVMs) remains a matter of debate. In the present study, the authors retrospectively evaluated the association of using a prescribed dose calculated utilizing the K index with the obliteration rate of cerebral AVMs after SRS.
C erebral arteriovenous malformations (AVMs) have been detected in population studies with an incidence of 1 in 100,000. 20 Their risk of intracranial hemorrhage ranges from 2% to 4% with potential catastrophic outcomes. 20 The recently published ARUBA (A Randomized Trial of Unruptured Brain Aneurysms) trial 17 has demonstrated even higher bleeding rates. The widespread use of neuroimaging has increased significantly the number of incidentally discovered malformations. Microsurgical resection or stereotactic radiosurgery (SRS), with or without prior endovascular embolization, are the major treatment options. While the former is often the first option for patients with small, superficial AVMs, the latter is an important tool for lesions in critical areas of the brain. Stereotactic radiosurgery has gained popularity in recent years. 1, 2, 4, 5, [7] [8] [9] [10] [11] [12] 21 Its effect on the obliteration of AVMs is gradual, with patients remaining at risk for hemorrhage during this latency period. Complete obliteration, after a single session, has been reported to vary between 60% and 80% over 5 years. 1, 2, 4, 5, 7, 21 Several metrics have been used to determine the appropriate prescribed dose during SRS for AVMs. One of the most widespread methods utilizes the K index, 14 first introduced in 1997 by Karrlson et al. at the Karolinska Institute, Sweden. The K index was calculated as the ratio of the margin dose over the cube root of the AVM Stereotactic radiosurgery of intracranial arteriovenous malformations and the use of the K index in determining treatment dose volume, and a K index of approximately 27 appeared to be optimal to obtain AVM obliteration with minimal risk of complications.
14 It was derived from the notion that an AVM was, in essence, a collection of parallel pipes, the length of which were related to the cube root of the volume. The statistical probability of a point thrombosis occurring due to SRS was proportionate to the length of the pipe. The constant K relating these factors was derived from empirical observation. The prescribed radiation dose is calculated based on the product of the cube root of the AVM volume and 27.
14 Despite its widespread use, however, this method has not been validated in an independent SRS cohort.
Utilizing the Cleveland Clinic Gamma Knife institutional review board-approved database, we examined our cohort of patients who underwent Gamma Knife radiosurgery (GKRS) for cerebral AVMs from 1997 to 2010 and compared the prescription dose assigned depending on the AVM volume. It became apparent that there was variability in the prescription dose in relation to the K index calculated dose, and the variability was associated with the AVM volume. We then compared the obliteration rate of cerebral AVMs among patients treated at a margin dose equal to or higher than the calculated dose based on the K index and patients treated at a lower margin dose. Other significant factors contributing to AVM obliteration were also investigated.
Methods

Cohort Definition
All patients undergoing GKRS for cerebral AVM treatment were registered prospectively in the Cleveland Clinic Gamma Knife database. After obtaining institutional review board approval, this database was queried from 1997 to 2010 to identify all patients who underwent GKRS for cerebral AVMs. Patients with planned staged treatments and prior AVM embolization were excluded. Patients with incomplete follow-up and incomplete AVM obliteration information were also excluded. Patients who required additional GKRS after an initial suboptimal result were included in the cohort.
Outcome Variables
The primary outcome variables were the rate of angiographic AVM obliteration and the rate of rebleeding. Angiographic obliteration was defined as lack of filling of the nidus at follow-up catheter angiography. Patients underwent MRI at regular intervals after GKRS. When MRI suggested resolution of the nidus, patients underwent cerebral angiography for confirmation. The timing of cerebral angiography varied for patients depending on the MRI findings and patient follow-up characteristics. The rate of rebleeding was also calculated based on the rate of symptomatic hemorrhage posttreatment.
Exposure Variables
The association of the outcomes with the pertinent exposure variables was examined using regression analyses. Age, AVM volume, AVM maximum dimension, margin dose, and maximum dose were continuous variables. Sex, presence of preoperative symptoms, preoperative hemorrhage, hemispheric location, presence of intranidal aneurysms, and AVM dose equal/higher or lower than the dose based on the K index were categorical variables. Spetzler-Martin grade and Pollock-Flickinger AVM score were ordinal variables. For some of the secondary analyses the AVM volume was divided into 3 groups: smaller than 2 cm 3 , 2-10 cm 3 , and larger than 10 cm 3 .
Radiosurgery Technique
The patients presented to the Cleveland Clinic Gamma Knife suite, and intravenous sedation was administered. The Leksell stereotactic G-frame (Elekta AB) was then affixed on the patient's head using 4 pins. In adults, the frame application was performed under local anesthesia, whereas in children general anesthesia was used. A high-resolution planning MR image with gadolinium was obtained followed by a high-resolution CT scan. All patients underwent biplanar stereotactic angiography on the day of treatment. The AVM nidus was typically delineated based on the T1-weighted volume with contrast sequence (MPRAGE), and the planning was calculated to cover 100% of the nidus volume. The margin dose was calculated based on the optimal K index according to the formula: prescribed dose = 27/(AVM volume 1/3 ). Patients for whom this calculated dose was deemed inappropriately high ended up receiving lower doses. Several different Leksell Gamma Knife units were used during the span of this study (models U, B, C, and 4C; Elekta AB). Corticosteroids were administered to patients at the conclusion of the treatment and as a short taper over the next few days.
Follow-Up
Patients were evaluated with MRI at 6, 12, 24, and 36 months after GKRS, when possible. In the case of adverse radiation events, imaging was performed with increased frequency. After 3 years, if MRI demonstrated likely obliteration of the AVM nidus, angiography was recommended. Arteriovenous malformation obliteration was defined as a lack of blood flow through the AVM nidus without signs of early draining vein on angiography. If residual nidus was visualized, then patients were typically recommended to undergo a second Gamma Knife treatment.
Statistical Analysis
Case characteristics were summarized using frequency counts for categorical variables and means, standard deviations, medians, and ranges for continuous variables. A univariate logistic regression model was used to determine the association between the obliteration rate and independent variables. Significant variables were subsequently tested in a multivariate logistic regression model. The rate of total obliteration and rate of bleeding post-GKRS were summarized using Kaplan-Meier curves. To examine the association between the AVM volume and the rate of total AVM obliteration, the cases were divided into 3 groups based on the AVM volume, and KaplanMeier analysis was performed. To examine the associa-tion between the divergence of the prescribed dose from the K index dose and the rate of total AVM obliteration, the cases were divided into the same 3 groups based on the AVM volume, and Kaplan-Meier and contingency table analyses were performed for each group comparing treatments performed at the K index dose or higher versus treatments performed at a lower dose. The separation of cases into groups based on the AVM volume prior to the analysis was necessary and was performed to eliminate confounding because it was noted that the majority of cases treated at a dose lower than the K index dose were in patients with AVM volumes smaller than 2 cm 3 . The secondary outcomes were compared using tests on contingency tables (chi-square test) for categorical variables or the Student t-test for continuous variables. All probability values are the results of 2-sided tests, and the level of significance was set at p < 0.05. Statistical analyses were performed using SPSS Statistics (version 20, IBM).
Results
Cohort Characteristics
In the study period there were 152 patients (Table 1) undergoing 165 GKRS treatments. For purposes of this analysis, each treatment is considered a separate case. The mean age at time of treatment was 43.6 years, and 53.9% of treatments were performed in females. In the majority of the cases (86.7%) patients presented with neurological deficits. Headache and focal neurological deficit (motor, sensory, visual, or speech) were most common (46.7% for each), and seizures were the presenting symptom in 21.8% of cases. Hemorrhage was an initial presentation in 24.8% of cases, and AVMs were discovered incidentally in only 13.3% of cases. The majority of the AVMs were located along the cerebral surface in the frontal, temporal, and parietal regions (25.5%, 23.6%, and 21.2%, respectively). The AVM nidus was associated with aneurysms in 13.3% of cases. In the majority of cases (82.4%) the AVMs belonged in Spetzler-Martin Grade II and III categories, and in 86.1% the Pollock-Flickinger AVM score was > 1. The mean AVM nidus volume ( ), the mean margin dose was 17.9 Gy (range 10-28 Gy), the mean maximal dose was 34.6 Gy (range 20-56 Gy), and the mean isodose line was 51.1 Gy (range 30-70 Gy).
Outcomes
Arteriovenous malformation obliteration was confirmed by angiography in 70 cases. The mean follow-up time was 36.2 months (range 1-158 months). Actuarial rates of obliteration were 44% at 3 years, 54% at 4 years, and 66% at 5 years and 80% for the entire range of our follow-up (12.5 years) (Fig. 1) . The median time until AVM obliteration was 40 months (95% CI 28.4-51.6 months). In the majority of cases (53.3%) patients experienced improvement of their preoperative symptoms after SRS, in 39.4% they experienced no change, and in 1.8% they experienced worsening of their preoperative symptoms after treatment. New neurological symptoms after SRS were seen in 23.4% of cases, and in 51.4% of these cases the patients' symptoms improved by the end of the follow-up period (Table 3) . A total of 3 CNS-related deaths were recorded during the follow-up period. One patient experienced a fatal intracerebral hemorrhage secondary to the AVM, 1 patient developed malignant cerebral edema, and 1 patient died of intractable seizure complications. Postoperative hemorrhage was recorded in 7 cases (4.2%) and all cases occurred during the first 6 months after treatment (Fig. 2) .
Arteriovenous malformation obliteration was significantly associated with AVM volume (Fig. 3) . The median time to obliteration for AVMs with a volume less than 2 cm 3 was 33 months (range 31-35 months), for AVMs with volume 2-10 cm 3 it was 39 months (range 29-48), and for AVMs > 10 cm 3 the median time was not reached during the time interval of the study.
Regression Analysis
Several variables potentially associated with rates of AVM obliteration were examined in a univariate regression model ( 
K Index Dose Stratification
In an attempt to assess the association between treating at the K index calculated dose and the rate of AVM obliteration, we divided our cohort between cases in which patients were treated at the calculated K index dose or above and cases in which they were treated below the K index dose. Overall, in 74 cases the patients were treated at the K index dose or above, and in 91 they were treated under the K index calculated dose. Comparison between the 2 subgroups did not reveal significant differences in terms of demographics, presentation, and post-SRS adverse symptoms and hemorrhage (Tables 1 and 3) . The group in which the treatment dose was lower than the K index calculated dose had a higher prevalence of brainstem AVMs and a lower prevalence of frontal lobe lesions and consisted of AVMs that belonged to a Spetzler-Martin Grade I-III and had an AVM score less than 2. In the cases in which a dose lower than the K index dose was used, the AVMs were also smaller in size and volume and received a higher maximum and margin dose compared with the cases in which a dose closer to the K index dose or above was delivered ( Table 2) .
Comparison of the AVM obliteration rates between the 2 groups did not demonstrate statistically significant differences in obliteration rates. In the majority of cases involving AVMs smaller than 2 cm 3 in volume, doses lower than the K index calculated dose were used, while in the majority of cases involving AVMs larger than 10 cm 3 in volume, the K index dose or a higher dose was delivered. Counterintuitively, there was a trend for higher obliteration rate in those cases in which a dose below the K index dose was used. Greater variability in dose assignment was noted for the cases involving AVMs between 2 cm 3 and 10 cm 3 in volume, where almost half were being treated at the K index dose and half were being treated at a lower dose (Table 5) . Obliteration rates were compared using contingency table analysis (chi-square test), and no significant difference was noted. For sensitivity analysis, the comparison of obliteration rates was also re- peated at fixed end points (24, 36, and 48 months) and again no significant differences were noted. Obliteration rates for each volume group were also compared using Kaplan-Meier curves by comparing curves of the total rate of obliteration for AVMs treated at/above or below the K index dose and using the log-rank test. No significant difference was noted for the AVMs overall and for each of the different AVMs based on volume (Fig. 4) . The marginal dose distribution was also compared for each of the AVM volume groups depending on their obliteration status (Fig. 5 ).
Discussion
Stereotactic radiosurgery is a central therapeutic intervention in the management of patients with cerebral AVMs. [7] [8] [9] [10] [11] [12] It is characterized by high obliteration rates, especially in small lesions, and low risk of adverse effects and complications. In the present retrospective study, we were not able to demonstrate an association of the optimal K index dose with improved obliteration rates, in comparison with smaller doses. The mean AVM volume in our series was 6.29 cm 3 and the mean margin dose was 17.9 Gy. This observation highlights the limitations in using the optimal K index dose to calculate the prescribed dose for an AVM.
The choice of SRS dose has been established based on target volume and AVM location, and it ranges from 16 to 25 Gy in most series. 3, 4 to be less effective in comparison with higher doses. In our series, we demonstrated that the AVM volume is an important predictive factor of AVM obliteration. The development of the optimal K index dose 14 was an effort to standardize SRS for AVMs, while minimizing complications; however, the K index dose calculation in AVMs with volumes less than 2 cm 3 can result in large prescription doses, which, in our series, led to treating small AVMs with lower than the K index dose. We were not able to demonstrate an association of this change to the prescription dose with changes in obliteration rates in our cohort. This underlines the importance of external validation of such indices or predictors of AVM obliteration, which are based on single-institution cohorts.
Arteriovenous malformation obliteration in our series was assessed with formal angiography, and actuarial rates of obliteration in our cohort were 44% at 3 years, 54% at 4 years, and 66% at 5 years. Obliteration rates ranging from 60% to 94% have been reported in the literature. [1] [2] [3] [4] [5] 7, 21 Arteriovenous malformations smaller than 10 cm 3 have demonstrated rates of 74%-100%. 19, 22 The use of angiography to define obliteration in our series partially explains the low rate we observed. Franzin et al. 5 have demonstrated a 10% increase in AVM obliteration rate, when considering the radiographic appearance of the lesion in MRI, in comparison with angiography. In addition, the median dose we prescribed is at the lower end of the reported spectrum, with a possible negative impact on AVM obliteration.
Various groups have attempted to identify factors that could predict the rate of obliteration of cerebral AVMs after SRS. [1] [2] [3] [4] [5] 7 Several series have identified low target volume as a factor associated with higher oblit- eration rates. 4 Kano et al. 7 have additionally recognized that a higher marginal dose is associated with improved outcomes. The Virginia group 21 has devised a predictive model of outcome after SRS based on the patient's age, AVM volume and eloquent location, history of hemorrhage, and embolization. Our univariate analysis demonstrated that lower volume, lower Spetzler-Martin grade, and lower Pollock-Flickinger score, as well as higher prescribed dose, were associated with improved outcomes. These associations were not significant when examined in a multivariate analysis.
One of the limitations of SRS is that patients are at risk of hemorrhage during the latency period. Radiosurgically treated AVMs show an annual bleeding rate of 2%-3% with a risk of hemorrhage of 3.7% in the first 5 years after radiosurgery and a bleeding frequency of 3.7% in the first 5 years after SRS. 6 Karlsson et al., 13 in a large series, demonstrated a 2.1% annual bleeding rate and a 0.9% permanent hemorrhage-related morbidity during the 2-year posttreatment latency period. Maruyama et al. 16 found a reduction in the bleeding rate by 54% during the latency period. Although conventional wisdom is that there is no protection against hemorrhage in an SRS-treated AVM until obliteration, all hemorrhages in our patient population occurred in the first 6 months posttreatment, despite an obliteration rate of less than 10% at 6 months. This result suggests that SRS may confer some protection against hemorrhage before obliteration occurs or that some patients suffering post-SRS hemorrhage were not captured in our database.
Another important component of radiosurgery is symptom control, while avoiding the development of radiation-induced complications. The majority of our patients experienced improvement in their symptoms posttreatment. However, about one-third of them developed new complaints, most of which persisted until the end of the observation period. Symptom control has been reported to range from 45% to 73% in several series. 18, 23 The present study has several limitations. Indication bias and residual confounding could account for some of the observed associations. In addition, the retrospective nature of the study introduces an obvious potential selection bias. Patients who did not receive the optimal K index dose had some contraindication during planning. However, this selection bias will push the results away from the null hypothesis, and therefore this argument strengthens the observed lack of association. In addition, our data are based on the practice of a small number of physicians in a single institution, resulting in limited generalization. Lastly, radiosurgery techniques have evolved over the year and the practice of our neurosurgeons has adapted to the new knowledge. It is likely that patients treated in the later years of this study benefited from our expanded knowledge and improving technique. 15 Further validation is warranted in large multicenter registries.
Conclusions
Stereotactic radiosurgery for cerebral AVMs remains an effective and safe treatment modality. Small AVMs may be prescribed doses smaller than the calculated K index dose without an effect in rates of obliteration. Higher margin dose and smaller AVM volume remain strong predictors of AVM obliteration. 
